TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29313267

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2536

Group type: COMPARATOR
Intervention: Placebo or Sitagliptin
Number of subjects: 2536
Study: 29313282

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once daily and Sitagliptin 100 mg once daily (E5/S100)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg once daily and Sitagliptin 100 mg once daily (E15/S100)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin groups
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study: 29313714

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator FEV1
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 396
Study: 29314424

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 3496

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3496
Study: 29314487

Group type: EXPERIMENTAL
Intervention: Clinical assessment of neck veins
Number of subjects: 0
Study: 29315015

Group type: EXPERIMENTAL
Intervention: Forced expression of a dominant-negative TGF-β receptor type 2 (DNRII)
Number of subjects: 8
Study: 29315307

Group type: EXPERIMENTAL
Intervention: Tenofovir exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29315327

Group type: EXPERIMENTAL
Intervention: Higher quality of care
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Quality of care
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Family planning programs with higher quality of care
Number of subjects: 1053
Study: 29315382

Group type: EXPERIMENTAL
Intervention: Contact force-sensing catheter ablation
Number of subjects: 261
Study: 29315999

Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg three times daily for 1 year
Number of subjects: 0
Study: 29316001

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir for 8 weeks
Number of subjects: 40
Study: 29316837

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/JAK2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids (standard first-line treatment)
Number of subjects: 0
Study: 29316897

Group type: EXPERIMENTAL
Intervention: Adolescents with higher AOD risk and lower mental health scores
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Adolescents asked by a medical provider about AOD use
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Adolescents at risk for AOD use and poor mental health
Number of subjects: 1279
Study: 29317222

Group type: EXPERIMENTAL
Intervention: Physical performance measures including muscle strength and mobility at discharge
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Total paretic lower limb torque and 6-minute walk test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Physical performance measures
Number of subjects: 75
Study: 29317381

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus full-time use of social networks (Facebook) for education and consultation.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional treatment.
Number of subjects: 128
Study: 29317417

Group type: EXPERIMENTAL
Intervention: New group-based treatment programme combining physical exercise and dietary therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 15
Study: 29317604

Group type: EXPERIMENTAL
Intervention: Baseline plasma kynurenine (KYN) concentrations
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: DEFB1 locus
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Functional studies of DEFB1
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: AHR involvement
Number of subjects: 290
Study: 29318039

Group type: EXPERIMENTAL
Intervention: 27-gauge pars plana vitrectomy (PPV)
Number of subjects: 47
Study: 29318647

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 635
Study: 29318759

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake of 500 mg/d higher
Number of subjects: 16156

Group type: EXPERIMENTAL
Intervention: Higher sodium intake
Number of subjects: 16156

Group type: EXPERIMENTAL
Intervention: Higher potassium intake
Number of subjects: 16156
Study: 29318795

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC (T1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC (T2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane at 2.0 MAC (T3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane increments (1.0-2.0 MAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of S' values between T1, T2, and T3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion rates at T1, T2, and T3
Number of subjects: 20
Study: 29319721

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at 0.04 U/min for one hour
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline noradrenaline dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noradrenaline dose higher than 0.38 mcg/kg/min
Number of subjects: 18
Study: 29319932

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg (single oral dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Younger control (18-45 years)
Number of subjects: 28
Study: 29320312

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab for HER2-amplified/overexpressing colorectal cancer
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Erlotinib for EGFR-altered tumors
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Vemurafenib for BRAF V600-mutated tumors
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Vismodegib for Hedgehog pathway-altered tumors
Number of subjects: 251
Study: 29320346

Group type: COMPARATOR
Intervention: Children with no bedroom media devices
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Children with bedroom media devices
Number of subjects: 90
Study: 29320994

Group type: EXPERIMENTAL
Intervention: Web-based continuing education program in blood pressure measurement (30-min online educational program)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Web-based continuing education program in blood pressure measurement
Number of subjects: 88
Study: 29321007

Group type: EXPERIMENTAL
Intervention: Staging laparoscopy (SL)
Number of subjects: 450
Study: 29321022

Group type: COMPARATOR
Intervention: Serum metabolic profiling using ultra high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) in IPF patients.
Number of subjects: 21

Group type: COMPARATOR
Intervention: LysoPC identified as a potential biomarker in serum of patients with IPF.
Number of subjects: 21
Study: 29321026

Group type: EXPERIMENTAL
Intervention: Combination intervention administered by trained lay health workers including appointment reminders via text and phone calls, follow-up and tracking for missed clinic visits, PMTCT health education at home visits and during clinic visits, and retention and adherence support and counseling.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination intervention administered by trained lay health workers.
Number of subjects: 0
Study: 29321034

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: New CMR diagnosis
Number of subjects: 154
Study: 29321041

Group type: EXPERIMENTAL
Intervention: Prophylactic proton pump inhibitor
Number of subjects: 3350
Study: 29321063

Group type: EXPERIMENTAL
Intervention: Local treatment with autologous adipose-derived stromal vascular fraction (ADSVF) and microfat; 14 ml of microfat and approximately 20 million viable ADSVF cells injected.
Number of subjects: 1
Study: 29321075

Group type: EXPERIMENTAL
Intervention: H1 vaccine alone (group 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: H1 formulated with the adjuvant IC31® (groups 2, 3, and 4)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: H1/IC31® vaccine (groups 2, 3, and 4)
Number of subjects: 39
Study: 29321126

Group type: EXPERIMENTAL
Intervention: SIAM text messages sent at 48 hours after discharge, then at day 8 and day 15, and months 1, 2, 3, 4, 5, and 6.
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: SIAM text messages
Number of subjects: 244
Study: 29321155

Group type: EXPERIMENTAL
Intervention: Plasminogen replacement therapy
Number of subjects: 0
Study: 29322062

Group type: EXPERIMENTAL
Intervention: High KT ratio
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (survived without progression)
Number of subjects: 96
Study: 29322091

Group type: EXPERIMENTAL
Intervention: Toca 511 (gamma retroviral replicating vector encoding cytosine deaminase) followed by 5-fluorocytosine (5-FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorocytosine (5-FC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toca 511 and Toca FC (extended-release 5-FC)
Number of subjects: 0
Study: 29322849

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 29324537

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 160
Study: 29324603

Group type: EXPERIMENTAL
Intervention: Pregnancy-associated hypertension (gestational hypertension and preeclampsia)
Number of subjects: 979

Group type: COMPARATOR
Intervention: Normotensive pregnancies (reference group)
Number of subjects: 979
Study: 29324745

Group type: EXPERIMENTAL
Intervention: Digital intervention for ADHD, 28 days of at-home treatment
Number of subjects: 80
Study: 29324985

Group type: EXPERIMENTAL
Intervention: Urine Tuberculosis Lipoarabinomannan
Number of subjects: 0
Study: 29324996

Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed viral respiratory infections (influenza, parainfluenza, rhinovirus, respiratory syncytial virus [RSV], adenovirus, human metapneumovirus [HMPV])
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Adenovirus, rhinovirus, and RSV
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Timing of respiratory infection (HMPV, RSV, influenza, rhinovirus, adenovirus)
Number of subjects: 1347
Study: 29325058

Group type: EXPERIMENTAL
Intervention: Serum levels of trimethyllysine (TML)
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Serum levels of palmitoylcarnitine
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Serum levels of γ-butyrobetaine
Number of subjects: 2519
Study: 29325121

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25OHD) concentrations in plasma
Number of subjects: 4114
Study: 29325133

Group type: EXPERIMENTAL
Intervention: Metformin (daily for 24 months)
Number of subjects: 119
Study: 29325161

Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) booster
Number of subjects: 0
Study: 29325173

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: N/A (All groups)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PCV13 or PPV23
Number of subjects: 44
Study: 29325238

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (not prescribed antidepressants)
Number of subjects: 124
Study: 29325434

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 323
Study: 29325521

Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m²)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 30
Study: 29325546

Group type: EXPERIMENTAL
Intervention: Irritation scale (9 items, alpha=0.88)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Debris scale (4 items, alpha=0.85)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Self-reports of puffy eyes
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Self-reports of red eyes
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Self-reports of debris
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Self-reports of irritation
Number of subjects: 907
Study: 29325548

Group type: EXPERIMENTAL
Intervention: Lung cancer screening decision aid video
Number of subjects: 50
Study: 29325578

Group type: EXPERIMENTAL
Intervention: Peer-led brisk walking programme (10-15 mins throughout the school week)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 199
Study: 29325583

Group type: EXPERIMENTAL
Intervention: Integrative care approach (IntCare)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (UsCare)
Number of subjects: 112
Study: 29325586

Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation (HFPV)
Number of subjects: 8
Study: 29325595

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 10% dextrose 5 mL/kg followed by a dextrose infusion in addition to standard care
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 1266
Study: 29325707

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) sampling using a 22-gauge needle
Number of subjects: 37
Study: 29326029

Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Pertuzumab (840 mg loading dose followed by 420 mg), Palbociclib (125 mg once a day for 21 days), Fulvestrant (500 mg every 4 weeks)
Number of subjects: 30
Study: 29326031

Group type: EXPERIMENTAL
Intervention: Stroop Task performance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Wisconsin Card Sorting Task (WCST) performance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (IGT) performance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inventory for Depressive Symptomatology (IDS-SR) scores
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multivariate linear model including Stroop interference and IDS-SR
Number of subjects: 46
Study: 29326093

Group type: EXPERIMENTAL
Intervention: Conventional face-to-face weight loss program
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Weight loss app program
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Partial face-to-face and partial app program (combi group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combi group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: App group
Number of subjects: 81
Study: 29326107

Group type: EXPERIMENTAL
Intervention: rs7903146 T allele homozygotes
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: T allele
Number of subjects: 608
Study: 29326293

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 0
Study: 29326298

Group type: EXPERIMENTAL
Intervention: Smoking duration
Number of subjects: 10187

Group type: COMPARATOR
Intervention: Pack-years
Number of subjects: 10187
Study: 29326320

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study: 29326651

Group type: EXPERIMENTAL
Intervention: 3-gradient direction DWI (3DWI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 20-gradient direction DWI (20DWI)
Number of subjects: 117
Study: 29326843

Group type: EXPERIMENTAL
Intervention: Restrictive approach to red blood cell transfusion
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Liberal approach to red blood cell transfusion
Number of subjects: 4800
Study: 29326917

Group type: EXPERIMENTAL
Intervention: Daily PrEP (one pill taken every day)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Event-driven PrEP (pills taken only around specific risk events)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Periodic PrEP (daily dosing during periods of increased risk)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 315
Study: 29327075

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day, oxaliplatin 85 mg/m2
Number of subjects: 35
Study: 29327182

Group type: EXPERIMENTAL
Intervention: 600 mg ferrous fumarate in tablet form (195 mg of elemental iron)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1390 mg ferrous gluconate as a solution (160 mg of elemental iron)
Number of subjects: 24
Study: 29327948

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 53
Study: 29329141

Group type: EXPERIMENTAL
Intervention: Spectralis optical coherence tomography (Heidelberg Engineering)
Number of subjects: 32
Study: 29329555

Group type: EXPERIMENTAL
Intervention: Exercise training (three supervised, high-intensity interval training sessions/week during NACRT and ≥150 min/week of unsupervised, moderate-to-vigorous-intensity continuous exercise training after NACRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (no increase in exercise from baseline)
Number of subjects: 60
Study: 29329568

Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y90) radioembolization
Number of subjects: 30
Study: 29329602

Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX (all csDMARDs pooled)
Number of subjects: 3113

Group type: COMPARATOR
Intervention: Abatacept plus non-MTX csDMARDs
Number of subjects: 3113

Group type: COMPARATOR
Intervention: Abatacept plus MTX
Number of subjects: 3113

Group type: COMPARATOR
Intervention: Abatacept plus one non-MTX csDMARD
Number of subjects: 3113
Study: 29329991

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced EUS (CE-EUS)
Number of subjects: 28
Study: 29329992

Group type: EXPERIMENTAL
Intervention: EUS elastography (strain ratio) - parenchymal strain ratio (pSR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS elastography (strain ratio) - wall strain ratio (wSR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS elastography with pSR cut-off at 9.10
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS elastography with wSR cut-off at 16.2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fractal analysis of malignant lesions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fractal analysis across all 3 channels (red, green, blue)
Number of subjects: 100
Study: 29330398

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 0
Study: 29330625

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (AET)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Initial necessity-concern beliefs about AET
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Expected side-effect severity
Number of subjects: 116
Study: 29330639

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 19
Study: 29330782

Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg single oral administration
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Vilaprisan administered with itraconazole
Number of subjects: 2
Study: 29330858

Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 cochlear implant
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 cochlear implant with electric-acoustic stimulation
Number of subjects: 32
Study: 29331245

Group type: EXPERIMENTAL
Intervention: Outsmart HPV intervention (population-targeted, individually-tailored content)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (standard HPV vaccination information)
Number of subjects: 150
Study: 29331936

Group type: EXPERIMENTAL
Intervention: Customized foot orthoses (CFO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No CFO utilization
Number of subjects: 20
Study: 29331969

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment initiated at diagnosis
Number of subjects: 3482

Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapy
Number of subjects: 3482
Study: 29331971

Group type: EXPERIMENTAL
Intervention: Lantern mobile cognitive-behavioural programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control)
Number of subjects: 0
Study: 29331988

Group type: EXPERIMENTAL
Intervention: HIV positive individuals (PLWHIV)
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 1098
Study: 29332626

Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: One-year post-surgery symptoms of depression
Number of subjects: 1125
Study: 29332633

Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety and depression)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Delta SPO
Number of subjects: 55
Study: 29333159

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation (MWA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 75
Study: 29333165

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of autologous VEGF-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29333880

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 764
Study: 29334265

Group type: EXPERIMENTAL
Intervention: Treated hypertension
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: New-onset hypertension during follow-up
Number of subjects: 320

Group type: COMPARATOR
Intervention: Uncontrolled treated hypertension
Number of subjects: 320
Study: 29334491

Group type: EXPERIMENTAL
Intervention: AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed
Number of subjects: 1085

Group type: COMPARATOR
Intervention: OLM/HCTZ 20/12.5 mg once daily titrated to 40/25 mg if needed
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: AZL-M/CTD lower dose
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: AZL-M/CTD higher dose
Number of subjects: 1085

Group type: COMPARATOR
Intervention: OLM/HCTZ
Number of subjects: 1085
Study: 29334907

Group type: EXPERIMENTAL
Intervention: Left lateral tilting position after subarachnoid block (SAB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Supine position after subarachnoid block (SAB)
Number of subjects: 105